SRTA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
74.1M
+2.2%
72.5M
+7.6%
67.4M
+0.9%
66.8M
+35.5%
49.3M
Cost of Revenue
57.3M
-0.1%
57.3M
+7.6%
53.3M
-3.4%
55.1M
+42.6%
38.6M
Gross Profit
16.8M
+10.5%
15.2M
+7.8%
14.1M
+21.0%
11.7M
+9.5%
10.7M
Operating Expenses
20.7M
+0.1%
20.6M
+20.7%
17.1M
-5.4%
18.1M
+11.1%
16.3M
R&D
0
0
0
+100.0%
-1354000
0
SG&A
15.1M
+8.2%
14.0M
-10.3%
15.6M
-7.3%
16.8M
+5.7%
15.9M
Operating Income
-3831000
+29.2%
-5408000
-81.8%
-2974000
+53.6%
-6405000
-13.9%
-5622000
EBITDA
3.5M
+12.0%
3.1M
+3512.8%
86.0K
+102.5%
-3397000
+13.3%
-3918000
Net Income
-7615000
+27.6%
-10516000
-588.2%
2.2M
+124.4%
-8833000
-115.4%
57.4M
EPS (Basic)
$-0.09
+25.0%
$-0.12
-500.0%
$0.03
+130.0%
$-0.10
-114.3%
$0.70
EPS (Diluted)
$-0.09
+25.0%
$-0.12
-500.0%
$0.03
+130.0%
$-0.10
-114.3%
$0.70
Shares (Diluted)
88.3M
+2.4%
86.2M
+1.0%
85.3M
+0.7%
84.7M
+2.8%
82.5M
Strata Critical Medical (SRTA) — Financials